LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 2019 and provided an update on recent progress.

PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR AAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated,

LONDON and NEW YORK , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health